Frontiers in Immunology (Sep 2023)

Upregulated Fcrl5 disrupts B cell anergy and causes autoimmune disease

  • Chisato Ono,
  • Shinya Tanaka,
  • Keiko Myouzen,
  • Takeshi Iwasaki,
  • Mahoko Ueda,
  • Yoshinao Oda,
  • Kazuhiko Yamamoto,
  • Yuta Kochi,
  • Yoshihiro Baba

DOI
https://doi.org/10.3389/fimmu.2023.1276014
Journal volume & issue
Vol. 14

Abstract

Read online

B cell anergy plays a critical role in maintaining self-tolerance by inhibiting autoreactive B cell activation to prevent autoimmune diseases. Here, we demonstrated that Fc receptor-like 5 (Fcrl5) upregulation contributes to autoimmune disease pathogenesis by disrupting B cell anergy. Fcrl5—a gene whose homologs are associated with human autoimmune diseases—is highly expressed in age/autoimmunity-associated B cells (ABCs), an autoreactive B cell subset. By generating B cell-specific Fcrl5 transgenic mice, we demonstrated that Fcrl5 overexpression in B cells caused systemic autoimmunity with age. Additionally, Fcrl5 upregulation in B cells exacerbated the systemic lupus erythematosus-like disease model. Furthermore, an increase in Fcrl5 expression broke B cell anergy and facilitated toll-like receptor signaling. Thus, Fcrl5 is a potential regulator of B cell-mediated autoimmunity by regulating B cell anergy. This study provides important insights into the role of Fcrl5 in breaking B cell anergy and its effect on the pathogenesis of autoimmune diseases.

Keywords